VA HB1405 | 2020 | Regular Session
Status
Spectrum: Partisan Bill (Republican 1-0)
Status: Introduced on January 8 2020 - 25% progression, died in committee
Action: 2020-02-11 - Left in Health, Welfare and Institutions
Pending: House Health, Welfare and Institutions Committee
Text: Latest bill text (Prefiled) [HTML]
Status: Introduced on January 8 2020 - 25% progression, died in committee
Action: 2020-02-11 - Left in Health, Welfare and Institutions
Pending: House Health, Welfare and Institutions Committee
Text: Latest bill text (Prefiled) [HTML]
Summary
Price transparency for prescription drugs for the treatment Price transparency for prescription drugs for the treatment of diabetes; civil penalty. Requires a manufacturer of a prescription drug indicated for use in the treatment of diabetes to report certain information to the Commissioner of Health regarding the cost of such prescription drugs and to report additional information when the price of such a drug increases beyond the increase in the medical care component of the Consumer Price Index for the preceding year. The bill also requires pharmacy benefits managers to report information to the Commissioner of Health regarding any rebates negotiated with a manufacturer for such drugs. The bill provides that such information reported to the Commissioner of Health will be managed by the nonprofit organization that administers the Virginia All-Payer Claims Database. The bill provides that the Board of Health may assess a civil penalty of up to $1,000 per week per violation, not to exceed a total of $50,000 per violation, against a manufacturer or pharmacy benefits manager that fails, within the Board's determination, to make a good faith effort to meet a reporting deadline. In addition, the bill requires pharmacy benefits managers to register with the State Corporation Commission and authorizes the Commission to revoke the registration of any pharmacy benefits manager that fails to comply with reporting requirements specified in the bill. The Board of Pharmacy is authorized to revoke the permit or registration of any manufacturer that fails
Title
Prescription drugs for the treatment of diabetes; price transparency, civil penalty.
Sponsors
Roll Calls
2020-02-03 - House - House: Subcommittee recommends striking from docket (6-Y 0-N) (Y: 6 N: 0 NV: 2 Abs: 0) [PASS]
History
Date | Chamber | Action |
---|---|---|
2020-02-11 | House | Left in Health, Welfare and Institutions |
2020-02-03 | House | Subcommittee recommends striking from docket (6-Y 0-N) |
2020-01-30 | House | Assigned HWI sub: Health |
2020-01-08 | House | Referred to Committee on Health, Welfare and Institutions |
2020-01-08 | House | Prefiled and ordered printed; offered 01/08/20 20100321D |
Code Citations
Chapter | Article | Section | Citation Type | Statute Text |
---|---|---|---|---|
32 | 1 | 276.4 | (n/a) | See Bill Text |
32 | 1 | 276.7:2 | (n/a) | See Bill Text |
38 | 2 | 3465 | (n/a) | See Bill Text |
38 | 2 | 3466 | (n/a) | See Bill Text |
38 | 2 | 3467 | (n/a) | See Bill Text |
54 | 1 | 3442.02 | (n/a) | See Bill Text |